Publication:
Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment

Simple item page
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorsAlan, Ozkan; Telli, Tugba Akin; Basoglu, Tugba; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Bozkurt, Suheyla; Atasoy, Beste Melek; Dane, Faysal; Yumuk, Perran Fulden
dc.date.accessioned2022-03-12T22:40:13Z
dc.date.available2022-03-12T22:40:13Z
dc.date.issued2020
dc.description.abstractObjectives: Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor. We aimed to evaluate the prognostic value of modified Glasgow Prognostic Score (mGPS), which is combination of C-reactive protein (CRP) and albumin, in recurrent high-grade glioma patients treated with systemic treatment. Patients and Methods: Data of 85 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 was retrospectively collected and analyzed. Patients were grouped according to mGPS criteria: mGPS-0: CRP 10 mg/L and albumin 3.5 g/dL or CRP 10 mg/L and albumin > 3.5 g/dL; and mGPS-2: CRP > 10 mg/L and albumin < 3.5 mg/L. We investigated the prognostic role of mGPS groups, mutations and survival outcomes. Results: There were 42 (49.4 %), 25 (29.6 %), and 18 (21 %) patients in mGPS-0, mGPS-1, and mGPS-2 groups, respectively. Median follow-up duration was 10 months (1-70 months). Median OS was 8.1 months. According to mGPS-0,-1 and-2; median OS was 13.8 months, 7.3 months and 3.6 months respectively (p = 0.003). mGPS, ATRX and IDH-1 mutation status, and ECOG PS were found to be independent prognostic factors for OS. Conclusion: In our study, mGPS was found to be an independent prognostic factor in patients with recurrent high-grade gliomas. If validated, mGPS can be used as an objective, easily calculated, cheap, and readily available prognostic model in routine practice.
dc.identifier.doi10.1016/j.clineuro.2020.105976
dc.identifier.eissn1872-6968
dc.identifier.issn0303-8467
dc.identifier.pubmed32531614
dc.identifier.urihttps://hdl.handle.net/11424/235922
dc.identifier.wosWOS:000571482200010
dc.language.isoeng
dc.publisherELSEVIER
dc.relation.ispartofCLINICAL NEUROLOGY AND NEUROSURGERY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectglioblastoma
dc.subjectGlasgow prognostic score
dc.subjecthigh grade gliomas
dc.subjectATRX status
dc.subjectoverall survival
dc.subjectCENTRAL-NERVOUS-SYSTEM
dc.subjectSINGLE-AGENT BEVACIZUMAB
dc.subjectACUTE-PHASE RESPONSE
dc.subjectSERUM-ALBUMIN LEVELS
dc.subjectINFLAMMATORY RESPONSE
dc.subjectSURVIVAL
dc.subjectCHEMOTHERAPY
dc.subjectTRIAL
dc.subjectIL-6
dc.subjectGPS
dc.titlePrognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment
dc.typearticle
dspace.entity.typePublication
local.avesis.id28ea7327-14ee-4336-9fcd-4e7006ab9d16
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber105976
local.journal.numberofpages7
local.journal.quartileQ3
oaire.citation.titleCLINICAL NEUROLOGY AND NEUROSURGERY
oaire.citation.volume196
relation.isAuthorOfPublication22ce1b48-93da-4e88-a61e-be24b5e6122a
relation.isAuthorOfPublication.latestForDiscovery22ce1b48-93da-4e88-a61e-be24b5e6122a

Files

Collections

Research Outputs